Skip to main content

Table 5 Cost-per-responder analysis

From: Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia

Primary Response Analysisa
  AboBoNT-A (N = 253) OnaBoNT-A (N = 103) All Patients (N = 356)
Unadjusted
 Mean Total Cost (€) 310.31 355.87 323.49
 Mean Response Rate 0.32 0.22 0.29
 Mean Cost-Per-Responder 969.23 1593.69 1107.33
Adjustedb
 Mean Total Cost (€) 314.18 346.35  
 Mean Response Rate 0.32 0.23  
 Mean Cost-Per-Responder 986.35 1523.77  
Alternative Response Analysisc
  AboBoNT-A (N = 251) OnaBoNT-A (N = 103) All Patients (N = 354)
Unadjusted
 Mean Total Cost (€) 310.30 355.87 323.56
 Mean Response Rate 0.34 0.19 0.30
 Mean Cost-Per-Responder 916.30 1832.75 1090.86
Adjustedb
 Mean Total Cost (€) 314.30 346.12  
 Mean Response Rate 0.34 0.20  
 Mean Cost-Per-Responder 931.45 1755.83  
  1. aResponse is defined as: ≥25% improvement in TWSTRS severity scores at visit 2, at least a 12 week interval between injection and subject report of treatment waning, no report of related severed adverse events a visit 2 or visit 3, and a Clinical Global Improvement (CGI) score equal to either + 2 or + 3 at visit 2
  2. bAdjusted for age, sex, prior treatment with BoNT-A, and use of EMG at baseline
  3. aboBoNT-A abobotulinumtoxinA; onaBoNT-A onabotulinumtoxinA
  4. cResponse is defined as: ≥25% improvement in TWSTRS severity scores at visit 3, and no report of a severe adverse event related to BoNT-A injection at visit 3